Physician profile
Alice E Hong
NPI 1003077991
$4,295.95
in general payments reported to CMS, 2019-2025
26 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $383 · 2021: $313 · 2022: $251 · 2023: $1,332 · 2024: $943 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.42 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $726.80 | 2019-2025 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Dompe US, INC. | $565.43 | 2019-2025 | Oxervate |
| Alcon Vision LLC | $564.85 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $459.12 | 2023-2025 | Miebo, Envista Mx60 Iol, Doctors Allergy Formula |
| Johnson & Johnson Surgical Vision, INC. | $396.01 | 2021-2025 | Veritas Vision System, Catalys System, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $231.76 | 2019-2025 | Cequa |
| Amgen INC. | $230.44 | 2021-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.47 | 2019-2021 | |
| Sight Sciences, INC. | $141.09 | 2024 | Omni Surgical System |
| Horizon Therapeutics Plc | $127.50 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $120.91 | 2023-2025 | Tyrvaya |
| Globus Medical, INC. | $100.23 | 2024 | Direct Look |
| Aerie Pharmaceuticals, INC. | $77.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.05 | 2019-2020 | |
| Shire North American Group INC | $58.46 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $50.19 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $41.65 | 2019-2023 | Flarex |
| Allergan, INC. | $39.95 | 2020 | |
| Depuy Synthes Sales INC. | $23.79 | 2025 | Teligen |
| Lilly USA, LLC | $22.61 | 2023 | Jardiance |
| Tarsus Pharmaceuticals, INC. | $20.73 | 2025 | Xdemvy |
| Array Biopharma INC | $20.07 | 2022 | |
| Biotissue Holdings INC. | $19.14 | 2024 | |
| Halozyme INC | $19.09 | 2019 | |
| Sirtex Medical INC | $16.92 | 2022 | |
| Thea Pharma INC. | $16.13 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.